Afﬁnia Therapeutics…announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy (DCM).

AFTX-201 - Affinia Therap

Jul 22, 2026